STING agonists can promote the activation of cytotoxic T cells and the production of cytokines and inhibit pancreatic cancer progression, so it is clear that STING agonists modulate the immune microenvironment of pancreatic cancer (91). Here, STING1 is linked to pancreatic neoplasm.